Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $1.45 billion. The enterprise value is $1.61 billion.
| Market Cap | 1.45B |
| Enterprise Value | 1.61B |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 39.86 million shares outstanding. The number of shares has decreased by -7.82% in one year.
| Current Share Class | 39.86M |
| Shares Outstanding | 39.86M |
| Shares Change (YoY) | -7.82% |
| Shares Change (QoQ) | -1.49% |
| Owned by Insiders (%) | 1.81% |
| Owned by Institutions (%) | 106.41% |
| Float | 39.13M |
Valuation Ratios
The trailing PE ratio is 103.31 and the forward PE ratio is 11.76. PCRX's PEG ratio is 1.18.
| PE Ratio | 103.31 |
| Forward PE | 11.76 |
| PS Ratio | 1.94 |
| Forward PS | 1.91 |
| PB Ratio | 2.15 |
| P/TBV Ratio | 3.95 |
| P/FCF Ratio | 8.07 |
| P/OCF Ratio | 7.72 |
| PEG Ratio | 1.18 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.98, with an EV/FCF ratio of 8.97.
| EV / Earnings | 109.96 |
| EV / Sales | 2.16 |
| EV / EBITDA | 12.98 |
| EV / EBIT | 49.03 |
| EV / FCF | 8.97 |
Financial Position
The company has a current ratio of 5.04, with a Debt / Equity ratio of 0.61.
| Current Ratio | 5.04 |
| Quick Ratio | 3.21 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 2.97 |
| Debt / FCF | 2.30 |
| Interest Coverage | 2.12 |
Financial Efficiency
Return on equity (ROE) is 2.05% and return on invested capital (ROIC) is 3.21%.
| Return on Equity (ROE) | 2.05% |
| Return on Assets (ROA) | 1.48% |
| Return on Invested Capital (ROIC) | 3.21% |
| Return on Capital Employed (ROCE) | 2.93% |
| Weighted Average Cost of Capital (WACC) | 5.08% |
| Revenue Per Employee | $900,077 |
| Profits Per Employee | $17,657 |
| Employee Count | 829 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.10 |
Taxes
In the past 12 months, PCRX has paid $3.01 million in taxes.
| Income Tax | 3.01M |
| Effective Tax Rate | 17.06% |
Stock Price Statistics
The stock price has increased by +65.03% in the last 52 weeks. The beta is 0.25, so PCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +65.03% |
| 50-Day Moving Average | 27.53 |
| 200-Day Moving Average | 24.46 |
| Relative Strength Index (RSI) | 83.61 |
| Average Volume (20 Days) | 2,641,018 |
Short Selling Information
The latest short interest is 8.08 million, so 20.26% of the outstanding shares have been sold short.
| Short Interest | 8.08M |
| Short Previous Month | 7.56M |
| Short % of Shares Out | 20.26% |
| Short % of Float | 20.64% |
| Short Ratio (days to cover) | 14.52 |
Income Statement
In the last 12 months, PCRX had revenue of $746.16 million and earned $14.64 million in profits. Earnings per share was $0.35.
| Revenue | 746.16M |
| Gross Profit | 591.01M |
| Operating Income | 32.83M |
| Pretax Income | 17.65M |
| Net Income | 14.64M |
| EBITDA | 123.97M |
| EBIT | 32.83M |
| Earnings Per Share (EPS) | $0.35 |
Balance Sheet
The company has $251.03 million in cash and $412.12 million in debt, with a net cash position of -$161.09 million or -$4.04 per share.
| Cash & Cash Equivalents | 251.03M |
| Total Debt | 412.12M |
| Net Cash | -161.09M |
| Net Cash Per Share | -$4.04 |
| Equity (Book Value) | 671.98M |
| Book Value Per Share | 16.87 |
| Working Capital | 493.20M |
Cash Flow
In the last 12 months, operating cash flow was $187.66 million and capital expenditures -$8.15 million, giving a free cash flow of $179.52 million.
| Operating Cash Flow | 187.66M |
| Capital Expenditures | -8.15M |
| Depreciation & Amortization | 91.14M |
| Net Borrowing | -220.24M |
| Free Cash Flow | 179.52M |
| FCF Per Share | $4.50 |
Margins
Gross margin is 79.21%, with operating and profit margins of 4.40% and 1.96%.
| Gross Margin | 79.21% |
| Operating Margin | 4.40% |
| Pretax Margin | 2.37% |
| Profit Margin | 1.96% |
| EBITDA Margin | 16.61% |
| EBIT Margin | 4.40% |
| FCF Margin | 24.06% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 7.82% |
| Shareholder Yield | 7.82% |
| Earnings Yield | 0.97% |
| FCF Yield | 12.39% |
Analyst Forecast
The average price target for PCRX is $33.57, which is -7.62% lower than the current price. The consensus rating is "Hold".
| Price Target | $33.57 |
| Price Target Difference | -7.62% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 6.74% |
| EPS Growth Forecast (3Y) | 18.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PCRX has an Altman Z-Score of 2 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2 |
| Piotroski F-Score | 8 |